A randomized clinical trial of exenatide onT2D v1
J. Xu
May 23, 2020
Citations
0
Citations
Journal
Journal name not available for this finding
Full text
Semantic Scholar
Key Takeaway Key Takeaway: Exenatide improves glucose control and reduces body weight in overweight/obese patients with type 2 diabetes, potentially reducing microalbuminuria and improving kidney function.
Abstract
Among the Chinese adults with diabetes, the proportion of overweight is 41.0%, the proportion of obesity is 24.3%, and the proportion of abdominal obesity is as high as 45.4% in 2008, which shows an increasing trend in recent years. Clinical studies have demonstrated that Asian people have higher levels of visceral fat than European and American populations. Obesity, especially abdominal obesity is closely associated with Diabetic Nephropathy (DN). exenatide improves glycemic control and reduces body weight in patients with T2DM. In animal studies, exenatide can ameliorate albuminuria and improve kidney function. However, only a few studies evaluate the microalbuminuria in human. This study aims to investigate the effect of exenatide on urinary albumin, obese indices and glucose control in overweight/obese patients with type 2 diabetes. ATTACHMENTS Protocol.doc DOI dx.doi.org/10.17504/protocols.io.bgsyjwfw PROTOCOL CITATION Jing Xu 2020. A randomized clinical trial of exenatide onT2D. protocols.io https://dx.doi.org/10.17504/protocols.io.bgsyjwfw